Compare AUUD & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | MBRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.4M |
| IPO Year | 2020 | 2016 |
| Metric | AUUD | MBRX |
|---|---|---|
| Price | $0.80 | $8.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | 175.2K | ★ 299.8K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.16 |
| 52 Week High | $38.64 | $15.75 |
| Indicator | AUUD | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 80.69 |
| Support Level | N/A | $2.12 |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.07 | 0.77 |
| MACD | -0.02 | 0.65 |
| Stochastic Oscillator | 13.52 | 79.83 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.